Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Intra-Cellular Therapies ( (ITCI) ) has provided an announcement.
On April 2, 2025, Intra-Cellular Therapies notified the Nasdaq Stock Market of its merger completion and plans to delist its shares from the Nasdaq Global Select Market. This move is part of a broader change in control as the company becomes a wholly-owned subsidiary of Johnson & Johnson, with the merger valued at approximately $14.6 billion. Following the merger, all previous directors resigned, and the company’s certificate of incorporation and bylaws were amended to align with those of the acquiring entity.
More about Intra-Cellular Therapies
YTD Price Performance: 56.54%
Average Trading Volume: 3,485,964
Technical Sentiment Signal: Sell
Current Market Cap: $14.05B
For an in-depth examination of ITCI stock, go to TipRanks’ Stock Analysis page.